



## OvaScience to Host Second Quarter 2016 Financial Results Conference Call

July 28, 2016

WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 28, 2016-- OvaScience<sup>SM</sup> (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. EDT on Thursday, August 4, 2016 to discuss second quarter 2016 financial results and provide a general corporate update.

The live call can be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and by providing the passcode 9515417. A live webcast of the conference call will be available online from the Investors section of the Company's website at [www.ovascience.com](http://www.ovascience.com).

A replay of the conference call will be available from 7:00 p.m. EDT on Thursday, August 4, 2016 through 11:59 p.m. EDT on Thursday, August 11, 2016, and may be accessed by visiting OvaScience's website or by dialing +1-888-843-7419 for U.S. callers and +1-630-652-3042 for international callers. The replay access code is 9515417.

### About OvaScience

OvaScience<sup>SM</sup> (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC<sup>SM</sup>) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT<sup>SM</sup> treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a non-commercial preceptorship training program with the OvaPrime<sup>SM</sup> treatment, which could increase a woman's egg reserve, and is developing the OvaTure<sup>SM</sup> treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit [www.ovascience.com](http://www.ovascience.com) and [www.augmenttreatment.com](http://www.augmenttreatment.com) and connect with us on [Twitter](#) and [Facebook](#).

###

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160728006406/en/>

Source: OvaScience

### Media and Investor Contact:

#### OvaScience

Jennifer Viera, + 1 617-420-8748

[jviera@ovascience.com](mailto:jviera@ovascience.com)